Radiation field design in the ACOSOG Z0011 (Alliance) Trial

Reshma Jagsi, Manjeet Chadha, Janaki Moni, Karla Ballman, Fran Laurie, Thomas A Buchholz, Armando Giuliano, Bruce G Haffty, Reshma Jagsi, Manjeet Chadha, Janaki Moni, Karla Ballman, Fran Laurie, Thomas A Buchholz, Armando Giuliano, Bruce G Haffty

Abstract

Purpose: ACOSOG Z0011 established that axillary lymph node dissection (ALND) is unnecessary in patients with breast cancer with one to two positive sentinel lymph nodes (SLNs) who undergo lumpectomy, radiotherapy (RT), and systemic therapy. We sought to ascertain RT coverage of the regional nodes in that trial.

Methods: We evaluated case report forms completed 18 months after enrollment. From 2012 to 2013, we collected all available detailed RT records for central review.

Results: Among 605 patients with completed case report forms, 89% received whole-breast RT. Of these, 89 (15%) were recorded as also receiving treatment to the supraclavicular region. Detailed RT records were obtained for 228 patients, of whom 185 (81.1%) received tangent-only treatment. Among 142 with sufficient records to evaluate tangent height, high tangents (cranial tangent border ≤ 2 cm from humeral head) were used in 50% of patients (33 of 66) randomly assigned to ALND and 52.6% (40 of 76) randomly assigned to SLND. Of the 228 patients with records reviewed, 43 (18.9%) received directed regional nodal RT using ≥ three fields: 22 in the ALND arm and 21 in the SLND arm. Those receiving directed nodal RT had greater nodal involvement (P < .001) than those who did not. Overall, there was no significant difference between treatment arms in the use of protocol-prohibited nodal fields.

Conclusion: Most patients treated in Z0011 received tangential RT alone, and some received no RT at all. Some patients received directed nodal irradiation via a third field. Further research is necessary to determine the optimal RT approach in patients with low-volume axillary disease treated with SLND alone.

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

© 2014 by American Society of Clinical Oncology.

Figures

Fig 1.
Fig 1.
CONSORT diagram. ALND, axillary lymph node dissection; SLND, sentinel lymph node dissection.
Fig 2.
Fig 2.
Representative examples of detailed radiation treatment records received and classified as receiving standard tangents, high tangents, or third-field treatment. (A) Standard tangents. (B) High tangents. (C and D) Third-field and matched tangents from a single patient.
Fig 3.
Fig 3.
Distribution of patients for whom detailed radiation treatment records were available. ALND, axillary lymph node dissection; PAB, posterior axillary boost; SC, supraclavicular; SLND, sentinel lymph node dissection.

References

    1. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–433.
    1. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA. 2011;305:569–575.
    1. Massimino KP, Hessman CJ, Ellis MC, et al. Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest. Am J Surg. 2012;203:618–622.
    1. Gainer SM, Hunt KK, Beitsch P, et al. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: A survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012;19:3152–3158.
    1. Caudle AS, Hunt KK, Tucker SL, et al. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on surgeon practice patterns. Ann Surg Oncol. 2012;19:3144–3151.
    1. Giuliano AE. Reply to letter: Are the standard tangential breast irradiation fields used in the ACOSOG Z0011 trial really covering the entire axilla? Ann Surg. 2013;257:e2.
    1. Alco G, Dincer M. Are the standard tangential breast irradiation fields used in the ACOSOG Z0011 trial really covering the entire axilla? Ann Surg. 2013;257:e1.
    1. Belkacemi Y, Allab-Pan Q, Bigorie V, et al. The standard tangential fields used for breast irradiation do not allow optimal coverage and dose distribution in axillary levels I-II and the sentinel node area. Ann Oncol. 2013;24:2023–2028.
    1. Haffty BG, Hunt KK, Harris JR, et al. Positive sentinel nodes without axillary dissection: Implications for the radiation oncologist. J Clin Oncol. 2011;29:4479–4481.
    1. Quality Assurance Review Center.
    1. Schlembach PJ, Buchholz TA, Ross MI, et al. Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51:671–678.
    1. Fisher B, Wolmark N, Bauer M, et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet. 1981;152:765–772.
    1. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–575.
    1. Caudle AS, Hunt KK, Kuerer HM, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: A practice-changing trial. Ann Surg Oncol. 2011;18:2407–2412.
    1. Reznik J, Cicchetti MG, Degaspe B, et al. Analysis of axillary coverage during tangential radiotherapy to the breast. Int J Radiat Oncol Biol Phys. 2005;61:163–168.
    1. Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol. 2011;29(suppl):80s. abstr LBA1003.
    1. Poortmans P, Struikmans H, Kirkove C, et al. Irradiation of the internal mammary and medial supraclavicular lymph nodes in stage I to III breast cancer: 10 year results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922/10925. Presented at the European Cancer Congress; September 27-October 1, 2013; Amsterdam, the Netherlands.
    1. National Cancer Institute. NCI's progress on IOM goals and recommendations. .

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir